AbbVie Inc (NYSE:ABBV) insider Laura J. Schumacher sold 145,510 shares of the company’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $96.71, for a total transaction of $14,072,272.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

AbbVie Inc (ABBV) traded up $1.15 on Friday, reaching $97.45. 11,189,152 shares of the company’s stock traded hands, compared to its average volume of 4,760,000. The company has a quick ratio of 1.32, a current ratio of 1.45 and a debt-to-equity ratio of 5.08. The company has a market cap of $155,340.00, a PE ratio of 18.33, a P/E/G ratio of 1.35 and a beta of 1.53. AbbVie Inc has a 1-year low of $59.27 and a 1-year high of $98.87.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 27th. The company reported $1.41 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.39 by $0.02. The business had revenue of $7 billion for the quarter, compared to analysts’ expectations of $7 billion. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. The business’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.21 EPS. research analysts forecast that AbbVie Inc will post 5.55 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be paid a dividend of $0.71 per share. The ex-dividend date of this dividend is Thursday, January 11th. This represents a $2.84 annualized dividend and a yield of 2.91%. This is a boost from AbbVie’s previous quarterly dividend of $0.64. AbbVie’s dividend payout ratio is currently 62.14%.

Institutional investors and hedge funds have recently bought and sold shares of the business. Acropolis Investment Management LLC bought a new position in shares of AbbVie in the 2nd quarter worth approximately $106,000. Franklin Parlapiano Turner & Welch LLC bought a new position in shares of AbbVie in the 1st quarter worth approximately $108,000. Hudock Capital Group LLC lifted its stake in shares of AbbVie by 109.5% in the 2nd quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock worth $111,000 after purchasing an additional 806 shares during the period. Ffcm LLC lifted its stake in shares of AbbVie by 167.2% in the 2nd quarter. Ffcm LLC now owns 1,539 shares of the company’s stock worth $111,000 after purchasing an additional 963 shares during the period. Finally, Bristlecone Advisors LLC bought a new position in shares of AbbVie in the 3rd quarter worth approximately $113,000. Institutional investors and hedge funds own 69.32% of the company’s stock.

Several brokerages recently commented on ABBV. UBS reissued a “neutral” rating on shares of AbbVie in a research report on Friday, October 13th. Jefferies Group increased their price objective on shares of AbbVie from $107.00 to $115.00 and gave the company a “buy” rating in a research report on Monday, October 16th. Cowen reissued a “hold” rating and set a $95.00 price objective (up from $70.00) on shares of AbbVie in a research report on Monday, September 11th. BMO Capital Markets reissued a “hold” rating and set a $84.00 price objective on shares of AbbVie in a research report on Tuesday, November 21st. Finally, Piper Jaffray Companies increased their price objective on shares of AbbVie to $115.00 and gave the company an “overweight” rating in a research report on Friday, October 27th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. AbbVie currently has an average rating of “Buy” and an average price target of $97.96.

ILLEGAL ACTIVITY NOTICE: “Laura J. Schumacher Sells 145,510 Shares of AbbVie Inc (ABBV) Stock” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/12/15/laura-j-schumacher-sells-145510-shares-of-abbvie-inc-abbv-stock.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Insider Buying and Selling by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.